

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12Q 1/68, 1/42, C07H 21/00	A1	(11) International Publication Number: WO 95/24505 (43) International Publication Date: 14 September 1995 (14.09.95)
(21) International Application Number: PCT/GB95/00490 (22) International Filing Date: 7 March 1995 (07.03.95) (30) Priority Data: 94301636.0 8 March 1994 (08.03.94) EP <i>(34) Countries for which the regional or international application was filed:</i> AT et al. (71) Applicant: AMERSHAM INTERNATIONAL PLC [GB/GB]; Amersham Place, Little Chalfont, Buckinghamshire HP7 9NA (GB). (72) Inventors: REEVE, Michael, Alan; 149 Greys Road, Henley-on-Thames, Oxon RG9 1TE (GB). ROBINSON, Philip, Steven; 98 Winslow Road, Wingrave, Aylesbury, Buckinghamshire HP22 4QB (GB). (74) Agent: PENNANT, Pyers; Stevens, Hewlett & Perkins, 1 Serjeants' Inn, Fleet Street, London EC4Y 1LL (GB).		(81) Designated States: AU, CA, JP, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i>
(54) Title: MODIFYING NUCLEOTIDE ANALOGUES (57) Abstract Fluorescently labelled dideoxynucleoside triphosphates are widely used as chain-terminators in Sanger dideoxy sequencing operations. But these unincorporated dye-terminators migrate in an electrophoresis gel and obscure the desired sequence ladder. This invention provides a method and a kit for modifying the unincorporated dye-terminators, e.g. by removal of a 5'-triphosphate group by chemical or enzymatic means e.g. by use of a phosphatase enzyme.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LV	Latvia	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

- 1 -

MODIFYING NUCLEOTIDE ANALOGUES

5

Fluorescently labelled dideoxynucleoside triphosphates (hereafter referred to as dye-terminators) have found widespread usage in DNA sequencing applications, DNA mapping applications and DNA labelling applications. These dideoxynucleoside triphosphate analogues can be incorporated in a base-specific manner onto the 3' end of a growing DNA chain with the aid of a suitable polymerase and buffer system.

15 As dye-terminators lack 3' hydroxyl groups, incorporation of such residues gives rise to DNA chains that can no longer be extended by means of the polymerase.

For example, in DNA sequencing applications, four different fluorophores are attached to ddATP, ddCTP, ddGTP and ddTTP respectively. Each of the (dye-terminator) dideoxy chain terminated products in a nested set originating from a primer will be characterised by a particular terminal base-specific fluorophore (and hence fluorescence emission wavelength under appropriate excitation conditions). Polyacrylamide gel electrophoresis of the nested set of such chain termination products can be coupled to fluorescence excitation and detection in order to call the sequence of bases from a particular DNA sample. (See WO 91/05060, herein incorporated by reference).

30 In practice the fluorophores attached to ddATP, ddCTP, ddGTP and ddTTP each imparts a small perturbation in the rate of migration of the nested set of chain termination products through polyacrylamide gels. This problem is easily overcome with the use of

35

- 2 -

appropriate mobility correction algorithms.

Commercially available dye-terminators currently exist for both Sequenase and Ampli Tag DNA polymerases.

5

Disadvantages of the Current Art:

One of the major drawbacks to the elegant applications in which dye-terminators can be employed concerns the removal of residual (unincorporated) dye-terminators after the base-specific incorporation of dye-terminators is complete. Residual (unincorporated) dye-terminators are intensely fluorescent and, for example, migrate within several regions of polyacrylamide sequencing gels in which fluorescent chain terminated fragments of interest are to be found. The residual (unincorporated) dye-terminators thus interfere with the base calling in these regions of the sequence.

10

15

In order to avoid problems such as the above, much effort needs to be invested in the removal of these residual (unincorporated) dye-terminators.

20

Current methods rely upon selective alcohol precipitation, phenol extraction, CTAB precipitation or column chromatography in order to remove residual (unincorporated) dye-terminators. (See, for example ABI User Bulletin 20, Dec 1991 herein incorporated by reference).

25

None of the above methods are particularly robust and all are both time consuming and difficult to automate.

30

Similar problems may arise when the chain-terminating nucleotide analogues are radioactively or otherwise labelled. Even unlabelled chain-terminating nucleotide analogues may be a nuisance during electrophoresis for sequencing purposes. Similar problems can also arise where

35

- 3 -

labelled nucleotides or nucleotide analogues (other than chain-terminating nucleotide analogues) are used for incorporation in a growing DNA chain.

5 The present invention addresses all these problems. In preferred embodiments it is both rapid and robust and is particularly suited to automation.

The Invention

10 In one aspect the invention provides a method of treating a solution containing one or more fluorescently-labelled nucleotides or analogues and DNA chains incorporating residues of the one or more fluorescently-labelled nucleotides or analogues, which method comprises modifying the one or more
15 fluorescently-labelled nucleotides or analogues without correspondingly modifying the residues of the one or more fluorescently-labelled nucleotides or analogues incorporated in the DNA chains.

20 In another aspect the invention provides a kit comprising:
a) a supply of nucleotides or analogues,
b) a polymerase enzyme,
c) a supply of one or more chain-terminating nucleotide analogues, either component a) or component
25 c) being fluorescently labelled, and
d) means for modifying at the 5'-position the nucleotides and/or nucleotide analogues.

30 The solution to be treated may typically be a solution destined to be applied to an electrophoresis gel as part of a standard sequencing or mapping operation. A nucleotide analogue is a chemical entity which is capable of being incorporated in a nucleic acid chain by means of a polymerase enzyme under base-specific pairing conditions.

35 The one or more nucleotides or analogues to be modified are fluorescently-labelled, i.e. labelled

- 4 -

with a moiety which emits fluorescence when illuminated with light of suitable wavelength. Usually unlabelled nucleotides or analogues will also be present.

5 The one or more fluorescently-labelled nucleotides or analogues to be modified may lack a 3'-hydroxyl group, by virtue of which they are usually chain-terminators. Examples are 3'-fluoro and 3'-azido nucleoside triphosphates. Of particular importance in connection with Sanger sequencing are 2', 3'-
10 dideoxynucleoside triphosphates. The method of this invention is expected to be useful when at least one chain-terminating nucleotide analogue is fluorescently labelled, and particularly when four chain-terminating nucleotides are labelled each with a different
15 fluorescent label.

In other circumstances, there may be present one or more fluorescently-labelled nucleotide analogues which are incorporated in growing nucleic acid chains without acting as chain-terminators. These can also be
20 subject to modification as described below.

All these fluorescently-labelled nucleotides or analogues have a 5'-triphosphate group which is negatively charged. This negative charge is partly responsible for their undesired migration during
25 electrophoresis. The modification of the invention preferably involves removal of one, two or preferably three phosphate moieties of this triphosphate group. Removal can readily be effected enzymatically, e.g. by the use of a phosphatase enzyme such as alkaline
30 phosphatase. Acid phosphatase has also been used with success. Alternatively, partial or complete removal of the triphosphate group can be effected by chemical techniques. Alternatively again, the triphosphate group can be altered, rather than removed, in such a
35 way that the modified nucleotide or analogue migrates through an electrophoresis gel at a different rate.

- 5 -

It is found in practice that the use of a phosphatase enzyme in this way overcomes the problem of interference by residual unincorporated dye-terminators with the base calling at regions of a sequencing gel.

5 It is not certain whether this effect results from the partial or complete removal of phosphate moieties of the 5'-triphosphate groups of the dye terminators. Probably unincorporated dye-terminators with a 5'-monophosphate group or a 5'-hydroxyl group do not
10 interfere while those with a 5'-diphosphate group may cause slight interference.

Nucleotides or analogues which have been incorporated in a growing DNA chain do not have such 5'-triphosphate groups. The mobility of these moieties
15 is governed by the nature of the DNA chain to which they are attached. This DNA chain may typically have a 5'-hydroxyl group, derived from a chemically synthesised oligodeoxyribonucleotide primer used to prime a nested set of polymerase catalysed DNA chains.
20 At the 3'-end of each chain is the residue of a chain-terminating nucleotide or analogue. Enzymatic or chemical treatment as described above will have no effect on the nested set of DNA chains or on their electrophoretic mobility. Enzymatic or chemical
25 treatment as specified will thus result in alteration of the mobility of any free nucleotides or analogues present, without correspondingly altering the mobility of DNA chains containing residues of those nucleotides or analogues. Thus after the enzymatic or chemical
30 treatment specified, the treated solution can if desired be subjected to electrophoresis in agarose, polyacrylamide, hydrolink or other electrophoretic gel or matrix, for sequencing or other purposes. Alternatively, other forms of separation are known and
35 are possible.

It may however be preferred to remove

- 6 -

fluorescently-labelled nucleotides or nucleosides or analogues which have not become incorporated in growing DNA chains, prior to subjecting the solution to electrophoresis. The enzymatic or chemical treatment specified above may modify the nucleotides or analogues in such a way as to make their removal from the solution easier. These modified nucleotides or nucleosides or analogues behave differently with respect for example to selective alcohol precipitation, CTAB precipitation, phenol extraction and column chromatography. For example, reduction of non-specific binding of nucleotides or nucleosides or analogues to magnetic beads has many advantages in the automation of DNA sequencing protocols.

It will often be preferred to subject the treated solution to alcohol precipitation. This treatment has the effect of concentrating the DNA, which comes down in the precipitate, removing salt, and removing at least part of the unincorporated nucleotides or analogues. The modified nucleotides or nucleosides or analogues, which result from the phosphatase enzyme treatment described, have a greater tendency (than do the unmodified nucleotides or analogues) to remain in solution. Hence the phosphatase enzyme treatment described enhances the effectiveness of a subsequent alcohol precipitation step.

A kit according to the invention includes standard ingredients, namely a) a supply of nucleotides or analogues generally all four nucleotides; b) a supply of a polymerase enzyme; and c) a supply of one or more chain-terminating nucleotide analogues. Either component a) or component c), most usually component c) is fluorescently labelled. In addition, the kit comprises d) means for modifying at the 5'-position the unincorporated nucleotides and/or nucleotide analogues

- 7 -

e.g. present in a sequencing solution. This means may suitably be a phosphatase enzyme such as alkaline phosphatase.

5 **Experimental**

Example 1

**Demonstration of the modification of the
Electrophoretic mobility of dye-terminators using
10 alkaline phosphatase**

 The commercially available ABI Amplitaq dye-terminator kit was used to set up 5 cycle sequencing reactions. The reactions were set up as laid out in the product protocol booklet. The template used was
15 1 μ g of M13 mp8, purified by centrifugation in a cesium chloride gradient. The primer used was 1.0 pmol of M13 Universal primer. Samples were overlaid with 50 μ l of light mineral oil and thermal cycled using the protocol as below.

20 Pre-denaturation at 93°C for 5 mins followed by 25 cycles of:

 Annealing at 50°C for 15 secs, extension at 60°C for 4 mins, and denaturation at 95°C for 30 secs.

25 Samples were recovered from under the oil overlay post-sequencing and Nos. 2-5 were subjected to calf intestinal alkaline phosphatase digestion at 10, 5, 2.5 and 1 μ l respectively. Digestion was carried out for 5 mins at 37°C. No. 1 was subjected to identical treatment without alkaline phosphatase.

30 Post-digestion, the samples were diluted with an equal volume of glycerol, and loaded onto a pre-formed 1% agarose gel. Gel-Electrophoresis was carried out for 30 mins at 200 mA, 200 V. The products were visualised by means of a UV transilluminator. The resulting
35 photograph was taken using Polaroid 667 film at f 5.6 for 1 sec.

- 8 -

5 The photograph of the gel (not reproduced here) demonstrates conclusively that unmodified dye-terminators migrate into the gel (Track 1), showing that they possess a net negative charge, whereas the alkaline phosphatase digested dye-terminators do not migrate into the gel, indeed they migrate slightly towards the -ve charged electrode, demonstrating that they now possess a slight +ve charge, due to removal of the 5' triphosphate group.

10

Example 2

Demonstration of removal of dye-terminator artefacts by the use of alkaline phosphatase

15 Two Amplitaq generated sequence ladders were set up as outlined in Example 1. One was subjected to alkaline phosphatase treatment again as outlined previously. The other remained untreated. Both samples were then ethanol precipitated by adding x 0.5 vol of 7.5 M ammonium acetate (10 μ l) and x 2.5 vol of fast magnetic purification particles in ethanol (100 μ l at 0.5 mg/ml particles). The precipitations were then allowed to go to completion for 30 mins at room temperature. The particles were then recovered from the solution by the addition of a magnetic field and the supernatants removed by vacuum aspiration. The recovered particles were washed in 500 μ l of ethanol, separated by magnetic field addition and the supernatant again removed. This washing step was repeated once more and repeated finally with the addition of 70% ethanol, as opposed to 100% ethanol. The particles were then resuspended in 30 μ l of 0.8 mM EDTA, 8% formamide. The sequences generated having dissolved in the aforementioned solution were separated from the particles by addition of the magnetic field, and transferred to a fresh tube. These samples were then concentrated to 3 μ l in a Savant vacuum

35

- 9 -

centrifuge, denatured at 92°C for 2 mins and loaded onto a 6% polyacrylamide gel on an ABI 373A DNA sequencer. The sequencer was run for 12 hours and the resulting two traces were generated using the Analysis software on the machine. The traces are reproduced in Figures 1 and 2. Figure 1 is the trace obtained with alkaline phosphatase treatment. Figure 2 is the trace obtained without alkaline phosphatase treatment.

Each figure is a trace of four different fluorescent signals (which are distinguished by colour in the original) against chain length obtained using commercial equipment operated under the recommended conditions. The chain length and the identity of each 3'-terminal nucleotide is indicated above the trace.

As can be seen from the traces the treatment of the generated sequence ladders with alkaline phosphatase causes removal of the dye-terminator artefacts, and allows for accurate base calling with the ABI analysis software (Figure 1). The untreated control sample produced a sequence that was readable only in parts, with other parts (e.g. the regions 0-100 and 190-210) being obscured by unincorporated dye-labelled nucleotide analogues, demonstrating well the problems of dye-terminator artefacts electrophoresing in the area of the sequence ladders (Figure 2).

- 10 -

CLAIMS

5

1. A method of treating a solution containing one or more fluorescently-labelled nucleotides or analogues and DNA chains incorporating residues of the one or more fluorescently-labelled nucleotides or analogues, which method comprises modifying the one or more fluorescently-labelled nucleotides or analogues without correspondingly modifying the residues of the one or more fluorescently-labelled nucleotides or analogues incorporated in the DNA chains.

10

15

2. A method as claimed in claim 1, wherein the one or more fluorescently-labelled nucleotides or analogues to be modified lack a 3'-OH group.

20

3. A method as claimed in claim 2, wherein the one or more fluorescently-labelled nucleotides or analogues to be modified are 2',3'-dideoxynucleoside triphosphates.

25

4. A method as claimed in any one of claims 1 to 3, wherein the modification is at the 5'-position of the one or more fluorescently-labelled nucleotides or analogues.

30

5. A method as claimed in claim 4, wherein the modification involves use of a phosphatase enzyme to remove at least one 5'-phosphate group of the one or more fluorescently-labelled nucleotides or analogues.

35

6. A method as claimed in claim 5, wherein the phosphatase enzyme is an alkaline phosphatase.

7. A method as claimed in claim 5 or claim 6, wherein the enzyme is used to remove a 5'-triphosphate group of the one or more fluorescently-labelled nucleotides or analogues.

40

- 11 -

8. A method as claimed in any one of claims 1 to 7, wherein the treated solution, containing the one or more modified fluorescently-labelled nucleotides or nucleosides or analogues and the DNA chains
5 incorporating residues of the one or more fluorescently-labelled nucleotides or analogues, is run on an electrophoresis sequencing gel.

9. A method as claimed in any one of claims 1 to 8, wherein the treated solution is subjected to alcohol
10 precipitation to concentrate and purify the DNA chains.

10. A kit comprising:

a) a supply of nucleotides or analogues,

b) a polymerase enzyme,

c) a supply of one or more chain-terminating

15 nucleotide analogues, either component a) or component

c) being fluorescently labelled, and

d) means for chemically modifying at the 5'-position the nucleotides and/or nucleotide analogues.


20

25

30


35

Fig. 1.




3/4

Fig.2.



4/4

Fig.2(Cont).



INTERNATIONAL SEARCH REPORT

Internati Application No
PCT/GB 95/00490

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C12Q1/68 C12Q1/42 C07H21/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO,A,93 06243 (THE UNITED STATES BIOCHEMICAL INC.) 1 April 1993 see example 6	1-10
A	ANALYTICAL BIOCHEMISTRY, vol. 216, 1994 ORLANDO, US, pages 1-14, RAO, V. 'direct sequencing of polymerase chain reaction-amplified DNA' see page 3 - page 6	1
A	WO,A,93 24655 (AMERSHAM INTERNATIONAL PLC.) 9 December 1993	1

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

14 June 1995

Date of mailing of the international search report

27. 06. 95

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+ 31-70) 340-3016

Authorized officer

Osborne, H

INTERNATIONAL SEARCH REPORT

Information on patent family members

Internat Application No
PCT/GB 95/00490

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9306243	01-04-93	AU-A- 2573992	27-04-93
		CA-A- 2119140	01-04-93
		EP-A- 0654091	24-05-95
		JP-T- 6510433	24-11-94
WO-A-9324655	09-12-93	EP-A- 0642590	15-03-95